reported a phase I/II clinical trial using DC and autologous tumor lysates for bone and soft tissue sarcoma conducted from 2008-2014, in which patients’ peripheral blood mononuclear cells (PBMCs) were extracted and induced into DCs and treated with autologous tumor lysates, TNF-α, and OK-432 (37, 38). The gene discussed is TNF; the disease is neoplasm.